DRG Epidemiology’s coverage of narcolepsy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of narcolepsy for each country, as well as annualized case counts projected to the national population.

Most patient populations in the major mature pharmaceutical markets are forecast over a period of 20 years.

Table of contents

  • Narcolepsy - Epidemiology - Mature Markets Data

Author(s): Alison Isherwood, MSc, MRes, PhD

Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


Related Reports

Narcolepsy - Current Treatment - Narcolepsy | Treatment Algorithms: Claims Data Analysis | US | Dashboard

A number of therapies from a range of drug classes are available to address the symptoms of narcolepsy, which include excessive daytime sleepiness and cataplexy. Despite many available pharmacologi...

View Details

Narcolepsy - Current Treatment - Treatment Algorithms Claims Data Analysis (US)

A number of therapies from a range of drug classes are available to address the symptoms of narcolepsy, which include excessive daytime sleepiness and cataplexy. Despite many available pharmacologi...

View Details